Patents Assigned to Texas Health Science Center
-
Publication number: 20060111388Abstract: Methods and compositions used for lowering intraocular pressure. More particularly, the methods and compositions for lowering intraocular pressure pertain to the use of at least a phenanthroline derivative in an ophthalmic delivery solution.Type: ApplicationFiled: November 18, 2005Publication date: May 25, 2006Applicant: University of North Texas Health Science Center at Fort WorthInventors: Adnan Dibas, Thomas Yorio, Ganesh Prasanna
-
Publication number: 20060106064Abstract: The present invention includes compositions and methods for the protection of one or more central nervous system cells from trauma, when administered before, during or after the trauma, wherein the composition includes an effective amount of a butyrophenone, e.g., a 1-linked phenyl butyrophenone that is electronegative along the butyl chain and/or a Sigma-1 receptor antagonist.Type: ApplicationFiled: November 3, 2005Publication date: May 18, 2006Applicant: University of North Texas Health Science Center at Fort WorthInventors: John Schetz, James Simpkins, Jeffery Talbert
-
Patent number: 7041499Abstract: The present invention relates to nucleic acid molecules encoding cell surface receptors on immune cells and the characteristic peptides that comprise these receptors. More specifically, the present invention concerns the use of synthetic and recombinant peptides comprising natural killer (“NK”) cell surface receptors. The synthetic and recombinant peptides are used to generate monoclonal antibodies that bind a specific NK cell surface receptor called CS1. The binding of the monoclonal antibody to the NK cell surface receptor leads to NK cell activation. In a particular embodiments of the present invention, the monoclonal antibodies are utilized in a method that inhibits the growth of tumor cells.Type: GrantFiled: December 12, 2001Date of Patent: May 9, 2006Assignee: University of North Texas Health Science CenterInventors: Porunellor A. Mathew, Kent Boles
-
Patent number: 7026306Abstract: The present invention relates to novel estrogen-related steroidal quinols and their use as prodrugs for phenolic estrogens and estrogen analogs. The quinols of the present invention provide improved physicochemical properties, increased bioavailability, and improved distribution into tissues and penetration across the blood-brain barrier when compared to phenolic estrogens and estrogen analogs.Type: GrantFiled: April 1, 2003Date of Patent: April 11, 2006Assignees: University of Florida Research Foundation, Inc., University of North Texas Health Science CenterInventors: Laszlo Prokai, Katalin Prokai, James Simpkins
-
Patent number: 6900036Abstract: Prion peptides exhibiting structural isomerism to wild-type prion peptide are disclosed. The invention further discloses methods of making prion isomers, compositions comprising prion isomers, and compositions and products comprising antibody to a prion isomer. Methods for screening a patient for a neuro-degenerative disease, and methods for treating a patient afflicted with a neuro-degenerative disease are also disclosed.Type: GrantFiled: December 19, 2001Date of Patent: May 31, 2005Assignee: University of Texas Health Science Center HoustonInventors: Jui-Yoa Chang, Bao-Yuan Lu
-
Publication number: 20040224995Abstract: The current invention comprises compositions and methods for protecting a neuronal cell of a subject from a toxic insult. The method includes delivering an effective amount of a neuroprotective compound to the neuronal cells before or after the toxic insult. The neuroprotective compounds contain a peroxisome proliferator activated receptor (“PPAR-&ggr;”) binding moiety with either a phenolic ring moiety or a prostaglandin (“PG”) with a reactive &agr;,&bgr;-unsaturated carbonyl group on the cyclopentenone ring. Other novel compounds are also disclosed. The toxic insult that impinges upon the neuronal cell may be an acute process, or chronic disease process. Oxidative stress (e.g. hydrogen peroxide, and glutamate), injury, and secondary physiological responses to injury are among the acute processes discussed. Clinical disease processes that comprise oxidative stress, inflammatory responses, strokes, Alzheimer's disease, dementia, and Parkinson's disease are also addressed.Type: ApplicationFiled: May 9, 2003Publication date: November 11, 2004Applicant: University of North Texas Health Science Center at Fort WorthInventors: James W. Simpkins, Paul Aoun
-
Patent number: 6673768Abstract: Transgene constructs for generating transgenic animals, wherein the transgene encodes a gene product which modulates transcription of a hypertrophy-sensitive gene, are provided. Further provided are recombinant vectors comprising the transgenes of the invention. Further provided are transgenic animals generated using the transgene constructs. Further provided are enzyme-based, cell-based, and whole-animal-based assays for detecting substances having therapeutic activity toward cardiac hypertrophy. Further provided are compositions comprising substances which modulate levels of active product of a hypertrophy-sensitive gene. Further provided are methods of treating cardiac hypertrophy.Type: GrantFiled: October 15, 1998Date of Patent: January 6, 2004Assignees: Board of Regents, The University of Texas System, University of North Texas Health Science CenterInventors: Stephen R. Grant, Eric N. Olson
-
Patent number: 6657104Abstract: Transgene constructs for generating transgenic animals, wherein the transgene encodes a gene product which modulates transcription of a hypertrophy-sensitive gene, are provided. Further provided are recombinant vectors comprising the transgenes of the invention. Further provided are transgenic animals generated using the transgene constructs. Further provided are enzyme-based, cell-based, and whole-animal-based assays for detecting substances having therapeutic activity toward cardiac hypertrophy. Further provided are compositions comprising substances which modulate levels of active product of a hypertrophy-sensitive gene. Further provided are methods of treating cardiac hypertrophy.Type: GrantFiled: October 15, 1998Date of Patent: December 2, 2003Assignees: Texas Systems, University of the Board of the Regents, University of North Texas Health Science CenterInventors: Stephen R. Grant, Eric N. Olson, Jeffrey D. Molkentin
-
Publication number: 20030176356Abstract: A pharmaceutical composition, containing a therapeutically effective amount of an endothelin (“ET”) antagonists and/or an endothelin-converting enzyme (“ECE”) inhibitors and a pharmaceutically acceptable carrier. The pharmaceutical composition is useful for treating normal-tension and primary open-angle glaucoma and prevents optic nerve damage and retinal ganglion cell death associated with these ocular diseases.Type: ApplicationFiled: April 24, 2002Publication date: September 18, 2003Applicant: University of North Texas Health Science CenterInventors: Thomas Yorio, Ganesh Prasanna, Adnan Dibas, Martha E. Stokely
-
Patent number: 6599526Abstract: The present invention is directed to an anti-adhesion patch, which is constructed using a tissue equivalent technique. The anti-adhesion patch comprises a collagenous material and at least one non-living cellular component. Also provided is a method for preventing tissue adhesions between organs and other tissues being operated upon during surgical procedures by utilizing the anti-adhesion patch disclosed herein.Type: GrantFiled: August 17, 2001Date of Patent: July 29, 2003Assignee: The University of North Texas Health Science Center at Fort WorthInventor: Slobodan Dan Dimitrijevich
-
Publication number: 20030113332Abstract: The present invention relates to nucleic acid molecules encoding cell surface receptors on immune cells and the characteristic peptides that comprise these receptors. More specifically, the present invention concerns the use of synthetic and recombinant peptides comprising natural killer (“NK”) cell surface receptors. The synthetic and recombinant peptides are used to generate monoclonal antibodies that bind a specific NK cell surface receptor called CS1. The binding of the monoclonal antibody to the NK cell surface receptor leads to NK cell activation. In a particular embodiments of the present invention, the monoclonal antibodies are utilized in a method that inhibits the growth of tumor cells.Type: ApplicationFiled: December 12, 2001Publication date: June 19, 2003Applicant: University of North Texas Health Science Center at Fort WorthInventors: Porunellor A. Mathew, Kent Boles
-
Patent number: 6537815Abstract: The invention includes the gene csrB, the RNA encoded thereby and methods of use thereof. csrB RNA binds to and antagonizes the ability of CsrA to down-regulate the production of certain metabolic products. This invention is also drawn to methods of using csrB polynucleotides, and combination of csrB polynucleotides and CsrA polypeptides and antibodies that bind to such combinations.Type: GrantFiled: December 13, 2000Date of Patent: March 25, 2003Assignee: University of North Texas, Health Science Center at Fort WorthInventor: Tony Romeo
-
Patent number: 6471958Abstract: The present invention provides a non-contracting tissue equivalent comprising at least one cellular component and at least one non-cellular component. The tissue equivalent closely resembles normal tissue in being substantially non-contracting. In addition, the non-contracting tissue equivalent is translucent, allowing direct visual observation of the different layers of cells in the tissue equivalent. The non-contracting tissue equivalent is useful for a variety of complete tissue replacements including skin and cornea. The non-contracting tissue equivalent is useful for in vitro testing, evaluation and screening of potential pharmaceuticals or consumer products, production of biocompatible clinical products for tissue replacement and augmentation, and research studies on fundamental aspects of tissue structure and function.Type: GrantFiled: February 1, 2001Date of Patent: October 29, 2002Assignee: University of North Texas Health Science CenterInventors: S. Dan Dimitrijevich, Robert W. Gracy
-
Patent number: 6284765Abstract: A composition formulated for dose-wise delivery to a breathing passageway of a human, the composition comprising a carrier solution containing (+)naloxone and a pharmacologically effective amount of at least one adrenergic agonist, the (+)naloxone and agonist forming a mixture in the carrier. The at least one adrenergic agonist is selected from the group consisting of epinephrine, isoproterenol, albuterol, aminophylline, beclomethasone, dyphylline, flunisolide, isoetharine, metaproterenol, oxtriphylline, terbutaline, theophylline, pseudoephedrine, phenylephrine, ephedrine and norepinephrine. That composition is delivered by an atomizer means such as a liquid sprayer or inhaler to treat nasal congestion and asthmatic attacks. Further provided by the invention is a cardiovascular and respiratory stimulating composition for administration to a patient in doses, the composition comprising a pharmacologically effective concentration of (+)naloxone in a carrier solution.Type: GrantFiled: April 27, 2000Date of Patent: September 4, 2001Assignee: The University of North Texas Health Science Center at Fort WorthInventor: James L. Caffrey
-
Patent number: 6268471Abstract: The invention includes a gene encoding csrA, the protein encoded thereby and methods of use thereof.Type: GrantFiled: June 1, 1995Date of Patent: July 31, 2001Assignee: University of North Texas Health Science Center at Forth WorthInventor: Tony Romeo
-
Patent number: 6228638Abstract: The invention includes the gene csrB, the RNA encoded thereby and methods of use thereof. csrB RNA binds to and antagonizes the ability of CsrA to down-regulate the production of certain metabolic products. This invention is also drawn to methods of using csrB polynucleotides, and combination of csrB polynucleotides and CsrA polypeptides and antibodies that bind to such combinations.Type: GrantFiled: July 9, 1998Date of Patent: May 8, 2001Assignee: University of North Texas, Health Science Center at Fort WorthInventor: Tony Romeo
-
Patent number: 6190304Abstract: The present invention is an intra-aortic circulatory enhancing apparatus for use in human patients to improve blood flow to other arteries continuous with the aorta of the patient. The apparatus comprises an internal inflation means located within the aorta of the patient and an external inflation means located outside of the patient. The internal inflation means can be an internal balloon coupled to a hollow extent which is operatively coupled to a blood communication means. The blood communication means can be a first hollow catheter tube in one embodiment. The external inflation means can be an external balloon coupled to a hollow extent running through the center of the balloon and continuous with a second hollow catheter tube. The blood communication means is coupled to the internal and external inflation means, allowing blood within the aorta to communicate with the secondary inflation means.Type: GrantFiled: July 13, 1999Date of Patent: February 20, 2001Assignee: University of North Texas Health Science Center at Fort WorthInventors: H. Fred Downey, Xiaoming Bian
-
Patent number: 6071875Abstract: Compositions and methods for treating glaucoma and ocular hypertension by using TGF.alpha. are disclosed.Type: GrantFiled: May 19, 1999Date of Patent: June 6, 2000Assignees: Alcon Laboratories, Inc., University of North Texas Health Science Center at Fort WorthInventors: Abbot F. Clark, Robert J. Wordinger
-
Patent number: 5846946Abstract: Plasmid DNA encoding at least one Borrelia genospecies antigen and methods for making and using such a plasmid are disclosed and claimed. The genospecies can be burgdorferi, garinii and/or afzelli. The antigen can be OspA and/or OspB and/or OspC. Compositions containing the plasmid DNA are useful for administration to a host susceptible to Lyme Disease for an in vivo response, such as a protective response, or for generating useful antibodies. The inventive plasmid can also be transfected into cells for generating antigens in vitro. And, the inventive plasmid can be prepared by isolating DNA (such as DNA coding for: promoter, leader sequence, antigen, and terminator) and performing a ligation or ligations, such as a three-way ligation. More particularly, administration of DNA encoding Borrelia genospecies antigen, e.g.Type: GrantFiled: June 14, 1996Date of Patent: December 8, 1998Assignees: Pasteur Merieux Serums et Vaccins, Vical Inc., University of Texas Health Science CenterInventors: Robert C. Huebner, Jon A. Norman, Xiaowu Liang, Kristin R. Carner, Alan G. Barbour, Catherine J. Luke
-
Patent number: 5486204Abstract: A method of treating severe brain trauma with hypothermia includes the introduction of specified medication to reduce the risk of cardiac arrhythmia and other malfunctions that may result from the brain trauma or the hypothermia. The method further includes a protocol for the treatment which defines time, temperature, rate of change of temperature, and the timing of the introduction of medications. Finally, rigidly controlled rewarming reduces the incidence of rewarming shock in recovering patients.Type: GrantFiled: September 20, 1994Date of Patent: January 23, 1996Assignee: University of Texas Health Science Center HoustonInventor: Guy L. Clifton